Cognitive Enhancers Flashcards

1
Q

e) Main drugs used to enhance cognitive performance (often in the absence of medical advice)

A

i) Caffeine
ii) Amphetamines
iii) Methylphenidate
iv) Modafinil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

i) improve mental performance in fatigued subjects (simple, tedious tasks)
ii) increase ability to focus and maintain self control. In addition to reducing fatigue,

A

g) Amphetamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

reduces fatigue and has a positive effect on long-term memory consolidation

A

h) Methylphenidate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

improves attention in rested individuals, while improving wakefulness, memory and executive functions in sleep-deprived individuals

A

i) Modafinil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ii) Overactivity and limited attention span disrupt their education and social development
iii) Thought to be disorder of NE and DA pathways in the frontal cortex and basal ganglia

A

2) ADHA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

2) ADHA

b) Characterized by co-existence of what three things?

A

i) Inattentive
ii) Hyperactivity
iii) Impulsive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

g) Brain Pathways and ADHD

i) Thought to be disorder of NE and DA pathways in the _____________ and _________

A

frontal cortex and basal ganglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

3) Neurotransmitters and ADHD

a) _________ (NE) and __________(DA) pathways are involved in maintaining and focusing attention

A

Prefrontal and mesocortical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

4) Drugs Used to Treat ADHD
a) CNS stimulants
i) Examples
___________ and ________
ii) 80% to 90% effective in children
iii) First-line treatments

A

(1) Amphetamines

(2) Methylphenidate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

5) CNS stimulants

A

b) Methylphenidate

a) Amphetamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

5) CNS stimulants

a) Amphetamines

A

i) Immediate-release (Dexedrine)

ii) Sustained-release (Dexedrine Spansules, and Adderall XR) formulations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

5) CNS stimulants

b) Methylphenidate

A

i) Immediate-release (Ritalin)

ii) Sustained-release (Concerta and Metadate CD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

a) Areas of the prefrontal and limbic cortex involved with focusing and maintaining attention and prioritizing behaviors are activated by psychostimulants at ___________ doses

A

low (therapeutic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

b) Areas of the brain involved in motor activity and arousal get activated at ___________ doses

A

higher (euphoric or toxic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

c) People who abuse amphetamine may develop reverse tolerance
i) Become psychotic with chronic use of the drug, even without dose escalation

A

sensitization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

a) Highly selective NE reuptake inhibitor

b) also elevates DA levels in the prefrontal cortex but not in the nucleus accumbens or the striatum

A

9) Atomoxetine (Strattera)

17
Q

c) Only ADHD medication that has no abuse potential

i) Not a controlled substance

A

9) Atomoxetine (Strattera)

18
Q

mediates the euphoric properties (i.e., abuse liability) of the psychostimulant

A

ii) Nucleus accumbens

19
Q

9) Atomoxetine (Strattera) Adverse effects

A

e) Adverse effects
i) nausea, vomiting, weight loss
ii) sleep problems
iii) liver damage

20
Q

10) Alzheimer Disease

Main pathological features

A

i) amyloid plaques
ii) neurofibrillary tangles
iii) loss of neurons (particularly cholinergic neurons of the basal forebrain)

21
Q

aggregates of the Aβ fragment of amyloid precursor protein (APP), a normal neuronal membrane protein, produced by the action of β- and γ-secretases

A

c) Amyloid plaques

22
Q

h) Loss of _____________is believed to account for much of the learning and memory deficit in AD

A

cholinergic neurons

23
Q

epidemiological studies suggested that some ______ reduce the likelihood of developing AD

A

NSAIDs

24
Q

a) Cholinesterase Inhibitors
b) _______ - first drug approved for treating AD
i) Enhancement of cholinergic transmission
ii) Slight improvements in tests of memory/cognition in ~40% of AD patients
iii) No improvement in other functional measures that affect quality of life

A

Tacrine

25
Q

a) Cholinesterase Inhibitors - Tacrine side effects

A

(1) Nausea, abdominal cramps, etc.

v) Hepatotoxicity, so no longer used

26
Q

i) Cholinesterase Inhibitors - Same basis as tacrine, also limited efficacy
ii) Produce a measurable, but slight, improvement of cognitive function in AD patients
iii) Less toxicity than tacrine

A

c) Donepezil, rivastigmine, galantamine

27
Q

d) Overall, small improvement in cognitive function, with no effect on disease progression.

A

e) Cholinesterase Inhibitors

28
Q

b) Weak antagonist at NMDA receptors
c) Orally active
d) Produces a modest cognitive improvement in moderate or severe AD
e) Not neuroprotective

A

a) Memantine

29
Q

f) Possible mechanism
i) Selective inhibition of excessive, pathological NMDA receptor activation
ii) Preserves more physiological NMDA receptor activation

A

Memantine

30
Q

g) Long plasma half-life
h) Used in conjunction with cholinesterase inhibitors or by itself
i) Slows cognitive deterioration and decreases caregiver burden for patients with moderate to severe AD

A

Memantine